Skip to main content

Advertisement

SpringerLink
Log in

Molecular pathology of Breast Cancer: Prognostic and predictive markers in this century and the next

  • Published:
Breast Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ER:

Estrogen receptor

SPF:

S-phase fraction

IHC:

Immunohistochemistry

EIA:

Enzyme immunoassay

ICRF:

Imperial Cancer Research Fund

DCIS:

Ductal carcinomain situ

CGH:

Comparative genomic hybridization

FISH:

Fluorescentin situ hybridization

References

  1. Jensen EV, DeSombre ER: Steroid hormone binding and hormone receptor. In: Holland JF, Frie E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR eds, Cancer Medicine, Lea & Febinger, Philadelphia, pp815–823, 1993.

    Google Scholar 

  2. Barnes DM, Harris WH, Smith P,et al: Immunohistochemical determination of oestrogen receptor; Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.Br J Cancer 74:1445–1451, 1996.

    PubMed  CAS  Google Scholar 

  3. Miles DW, Harris WH, Gillett CE,et al: The effect of cerbB2 and oestrogen receptor status on survival of women with primary breast cancer treated with adjuvant CMF. Int J Cancer 84:354–359, 1999.

    Article  PubMed  CAS  Google Scholar 

  4. Gillett C, Fantl V, Smith R,et al: Amplification and overexpression of cyclin Dl in breast cancer detected by immunohistochemical staining.Cancer Res 54:1812–1817, 1994.

    PubMed  CAS  Google Scholar 

  5. Gillett C, Smith P, Gregory W,et al:Cyclin Dl and prognosis in human breast cancer.Int J Cancer 69:92–99, 1996.

    Article  PubMed  CAS  Google Scholar 

  6. Fredersdorf S, Burns J, Milne AM,et al: High level expression of p27kipl in proliferating tumour cells and its inverse correlation with the degree of malignancy in human breast colorectal tumours.Proc Natl Acad Sci USA 94:6380–6385, 1997.

    Article  PubMed  CAS  Google Scholar 

  7. Gillett CE, Smith P, Peters G,et al: Cyclin dependent kinase inhibitor p27kipl expression and interaction with other cell cycle associated proteins in mammary carcinoma.J Pathol 187:200–206, 1999.

    Article  PubMed  CAS  Google Scholar 

  8. Gullick WJ, Love SB, Wright C,et al: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.Br J Cancer 63:434–438, 1991.

    PubMed  CAS  Google Scholar 

  9. Barnes DM, Dublin EA, Fisher CJ,et al: Immunohistochemical detection of p53 protein in mammary carcinoma; An important new independent indicator of prognosis.Human Pathol 24:469–476, 1993.

    Article  CAS  Google Scholar 

  10. Dublin EA, Miles DW, Rubens RD,et al: p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer.Int J Cancer (Pred Oncol) 74:605–608, 1997.

    Article  CAS  Google Scholar 

  11. Camplejohn RS, Ash C, Gillett CE,et al: The prognostic significance of DNA flow cytometry in breast cancer; Results from 881 patients treated in a single centre.Br J Cancer 71:140–145, 1995.

    PubMed  CAS  Google Scholar 

  12. Korenman SG, Dukes BA: Specific estrogens binding by the cytoplasm of human breast carcinoma.Clin Endocrinol Metab 30:639–645, 1970.

    CAS  Google Scholar 

  13. Cooper LS, Gillett CE, Smith PE,et al: Cell proliferation measured by MIB1 and timing of surgery for breast cancer.Br J Cancer 77:1502–1507, 1998.

    PubMed  CAS  Google Scholar 

  14. O’Reilly SM, Camplejohn RS, Barnes DM,et al: Nodenegative breast cancer; Prognostic subgroups defined by tumour size and flow cytometry.J Clin Oncol 8:2040–2046, 1990.

    PubMed  CAS  Google Scholar 

  15. Nielsen NH, Emdin SO, Cajander J,et al: De-regulation of cyclin E and Dl in breast cancer is associated with inactivation of the retinoblastoma protein.Oncogene 14:295–304, 1997.

    Article  PubMed  CAS  Google Scholar 

  16. Barnes DM, Gillett CE: Cyclin Dl in breast cancer.Br Cancer Res Treat 52:1–15, 1998.

    Article  CAS  Google Scholar 

  17. Barnes DM, Lammie GA, Millis RR,et al: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.Br J Cancer 58:448–452, 1988.

    PubMed  CAS  Google Scholar 

  18. Barnes DM: c-erbB-2 amplification in mammary carcinoma.J Cell Biochem 17G:132–138, 1993.

    Article  CAS  Google Scholar 

  19. Bartkova J, Barnes DM, Millis RR,et al: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.Human Pathol 21:1164–1167, 1990.

    Article  CAS  Google Scholar 

  20. Barnes DM, Bartkova J, Camplejohn RS,et al: Overexpression of the c-erbB-2 oncoprotein; Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance.Eur J Cancer 28:644–648, 1992.

    Article  PubMed  CAS  Google Scholar 

  21. Barnes DM, Camplejohn RS: p53, apoptosis and breast cancer.J Mam Gland Biol Neo 1:163–175, 1996.

    Article  CAS  Google Scholar 

  22. Houston SJ, Plunkett TA, Barnes DM,et al: Overexpression of c-erbB2 is a marker of resistance to endocrine therapy in advanced breast cancer.Br J Cancer 79:1220–1226, 1999.

    Article  PubMed  CAS  Google Scholar 

  23. Allred DC, Harvey JM, Berardo M,et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol 11:155–169, 1998.

    PubMed  CAS  Google Scholar 

  24. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer; An overview of the randomised trials.Lancet 351:1451–1467, 1998.

    Article  Google Scholar 

  25. Baselga J, Seidman AD, Rosen PP,et al: HER2 overexpression and paclitaxel sensitivity in breast cancer; Therapeutic implications.Oncology ll(Suppl 2):43–48, 1997.

    Google Scholar 

  26. Yu D, Liu B, Tan M,et al: Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.Oncogene 13:1359–1365, 1996.

    PubMed  CAS  Google Scholar 

  27. Slamon D, Leyland-Jones B, Shak S,et al: Addition of herceptin (humanised anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer multinational controlled phase III trial.Proceedings of the American Society of Clinical Oncology 17:98a, 1998.

    Google Scholar 

  28. Cardiff RD: Cellular and molecular aspects of neoplastic progression in the mammary gland.Eur J Cancer 24:15–21, 1988.

    Article  CAS  Google Scholar 

  29. Lampejo OT, Barnes DM, Smith P,et al: Evaluation of infiltrating ductal carcinomas with a DCIS component; Correlation of the histological type of the in situ component with grade of the infiltrating component.Semin Diag Pathol 11:215–222, 1994.

    CAS  Google Scholar 

  30. Millis RR, Barnes DM, Lampejo OT,et al: Does mammary tumour grade progress?; A study of the correlation between DCIS type, tumour grade and grade of recurrent breast carcinoma.Eur J Cancer 34:548–553, 1998.

    Article  PubMed  CAS  Google Scholar 

  31. Roylance R, Gorman P, Harris W,et al: Comparative genomic hybridisation of breast tumours stratified by histological grade reveals new insights into the biological progression of breast cancer.Cancer Res 59:1433–1436, 1999.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hedley Atkins/ICRF Breast Pathology Laboratory, Guy’s Hospital, SE1 9RT, UK, London

    Diana M. Barnes

Authors
  1. Diana M. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Barnes, D.M. Molecular pathology of Breast Cancer: Prognostic and predictive markers in this century and the next. Breast Cancer 6, 275–282 (1999). https://doi.org/10.1007/BF02966439

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966439

Key words

Search

Navigation